|
US20030108548A1
(en)
*
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
US20040002587A1
(en)
*
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8968730B2
(en)
*
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
EP1534335B9
(en)
*
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
EP1639014B1
(en)
*
|
2003-06-13 |
2010-09-22 |
Biogen Idec MA Inc. |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
GB0324368D0
(en)
*
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
ES2672640T3
(es)
*
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
US20050249723A1
(en)
*
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
|
EP1737890A2
(en)
*
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005110474A2
(en)
*
|
2004-05-10 |
2005-11-24 |
Macrogenics, Inc. |
HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
EA014226B1
(ru)
*
|
2004-07-26 |
2010-10-29 |
Байоджен Айдек Ма Инк. |
Антитела к cd154, их фрагменты и способы применения антител и фрагментов
|
|
KR20070057839A
(ko)
*
|
2004-08-19 |
2007-06-07 |
제넨테크, 인크. |
변경된 이펙터 기능을 갖는 폴리펩티드 변이체
|
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
EP1810035A4
(en)
*
|
2004-11-10 |
2010-03-17 |
Macrogenics Inc |
GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
DK1817340T3
(da)
*
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2006076594A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
WO2006105062A2
(en)
*
|
2005-03-29 |
2006-10-05 |
Verenium Corporation |
Altered antibody fc regions and uses thereof
|
|
WO2006110593A2
(en)
*
|
2005-04-07 |
2006-10-19 |
Macrogenics, Inc. |
Biological targets for the diagnosis, treatment and prevention of cancer
|
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9963510B2
(en)
*
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9284375B2
(en)
*
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2006116260A2
(en)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation of antibody effector function by hinge domain engineering
|
|
CA2605697A1
(en)
*
|
2005-04-26 |
2006-11-02 |
Bioren, Inc. |
Method of producing human igg antibodies with enhanced effector functions
|
|
CA2614181A1
(en)
*
|
2005-07-01 |
2007-01-11 |
Medimmune, Inc. |
An integrated approach for generating multidomain protein therapeutics
|
|
AU2006267090B2
(en)
*
|
2005-07-11 |
2013-03-07 |
Provention Bio, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
HUE029465T2
(en)
*
|
2005-08-10 |
2017-02-28 |
Macrogenics Inc |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2619298C
(en)
*
|
2005-08-26 |
2017-07-04 |
Glycart Biotechnology Ag |
Modified antigen binding molecules with altered cell signaling activity
|
|
WO2007041635A2
(en)
*
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
WO2007044616A2
(en)
|
2005-10-06 |
2007-04-19 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
KR20080073293A
(ko)
|
2005-10-14 |
2008-08-08 |
메디뮨 엘엘씨 |
항체 라이브러리의 세포 디스플레이
|
|
CA2644903A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
|
WO2007108152A1
(ja)
*
|
2006-03-23 |
2007-09-27 |
Tohoku University |
高機能性二重特異性抗体
|
|
US7786270B2
(en)
*
|
2006-05-26 |
2010-08-31 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
WO2008030564A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Verenium Corporation |
Aglycosylated antibodies and methods of making and using those antibodies
|
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
|
US20100015142A1
(en)
*
|
2006-12-21 |
2010-01-21 |
Macrogenics Inc. |
Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
ES2538990T3
(es)
*
|
2007-01-24 |
2015-06-25 |
Kyowa Hakko Kirin Co., Ltd. |
Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada
|
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
|
AU2008247819B2
(en)
|
2007-05-01 |
2013-02-14 |
Research Development Foundation |
Immunoglobulin Fc libraries
|
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
|
EP3424951A1
(en)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
AU2009258063B2
(en)
|
2007-06-21 |
2014-09-25 |
Macrogenics, Inc. |
BCR-complex-specific antibodies and methods of using same
|
|
WO2009006520A1
(en)
*
|
2007-07-03 |
2009-01-08 |
Medimmune, Llc |
Hinge domain engineering
|
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
US7892760B2
(en)
|
2007-11-19 |
2011-02-22 |
Celera Corporation |
Lung cancer markers, and uses thereof
|
|
US8795667B2
(en)
*
|
2007-12-19 |
2014-08-05 |
Macrogenics, Inc. |
Compositions for the prevention and treatment of smallpox
|
|
RU2529951C2
(ru)
|
2007-12-26 |
2014-10-10 |
Ксенкор, Инк. |
ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
CN107325182A
(zh)
|
2008-04-02 |
2017-11-07 |
宏观基因有限公司 |
HER2/neu‑特异性抗体和其使用方法
|
|
ES2675730T3
(es)
*
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
|
|
CN102281903B
(zh)
*
|
2008-11-17 |
2013-11-13 |
弗·哈夫曼-拉罗切有限公司 |
降低大分子在生理条件下聚集的方法和配方
|
|
EP2376109B1
(en)
|
2008-12-19 |
2019-01-23 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
TW201031749A
(en)
*
|
2009-02-10 |
2010-09-01 |
Otsuka Chemical Co Ltd |
IgG-Fc fragment and method for manufacturing the same
|
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
DE102009013748B4
(de)
*
|
2009-03-17 |
2012-01-26 |
Paul-Ehrlich-Institut |
Bestimmung von Interaktionen konstanter Antikörperteile mit Fc-gamma Rezeptoren
|
|
AU2010270979B2
(en)
*
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
|
CA2766065C
(en)
*
|
2009-06-30 |
2020-07-21 |
Research Development Foundation |
Immunoglobulin fc polypeptides
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス，インコーポレーテッド |
Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
EP2601216B1
(en)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
JP5866130B2
(ja)
|
2010-09-10 |
2016-02-17 |
アペクシジェン， インコーポレイテッド |
抗ＩＬ−１β抗体およびその使用方法
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
TWI812066B
(zh)
|
2010-11-30 |
2023-08-11 |
日商中外製藥股份有限公司 |
具有鈣依存性的抗原結合能力之抗體
|
|
AU2012205301B2
(en)
|
2011-01-14 |
2017-01-05 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
|
CN112812184A
(zh)
|
2011-02-25 |
2021-05-18 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
|
KR20140043724A
(ko)
|
2011-03-03 |
2014-04-10 |
아펙시젠, 인코포레이티드 |
항-il-6 수용체 항체 및 사용 방법
|
|
CA2827759C
(en)
|
2011-03-10 |
2018-10-16 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
|
SG10201602394QA
(en)
|
2011-03-29 |
2016-05-30 |
Roche Glycart Ag |
Antibody FC Variants
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
WO2012145746A1
(en)
|
2011-04-21 |
2012-10-26 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for the treatment of neuromyelitis optica
|
|
CN113461819B
(zh)
|
2011-04-29 |
2024-01-02 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
DK2714733T3
(da)
|
2011-05-21 |
2019-05-06 |
Macrogenics Inc |
Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
|
|
CA2836873C
(en)
|
2011-05-21 |
2019-10-22 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
CN109517059B
(zh)
*
|
2011-06-30 |
2023-03-28 |
中外制药株式会社 |
异源二聚化多肽
|
|
EP2742067A4
(en)
|
2011-08-12 |
2015-03-04 |
Omeros Corp |
MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
|
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン，エルエルシー |
抗ｂ７−ｈ４抗体およびその使用
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
EP3680251A1
(en)
*
|
2011-09-30 |
2020-07-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules for promoting elimination of antigens
|
|
US9441042B2
(en)
|
2011-11-02 |
2016-09-13 |
Apexigen, Inc. |
Anti-KDR antibodies and methods of use
|
|
CA2854233C
(en)
|
2011-11-04 |
2020-05-12 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
JP6124800B2
(ja)
|
2011-11-30 |
2017-05-10 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
|
|
EP2812027A1
(en)
|
2012-02-07 |
2014-12-17 |
Innate Pharma |
Mica binding agents
|
|
JP6226752B2
(ja)
|
2012-02-09 |
2017-11-08 |
中外製薬株式会社 |
抗体のＦｃ領域改変体
|
|
US20150065690A1
(en)
*
|
2012-04-27 |
2015-03-05 |
Bioatla, Llc |
Modified antibody regions and uses thereof
|
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
WO2013166594A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
LT3495387T
(lt)
|
2012-07-13 |
2021-11-25 |
Roche Glycart Ag |
Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
|
CN116574185A
(zh)
|
2012-07-25 |
2023-08-11 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
|
TW202237660A
(zh)
|
2012-08-24 |
2022-10-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
AU2013337903B2
(en)
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
CN111961134B
(zh)
|
2012-12-10 |
2024-04-05 |
比奥根Ma公司 |
抗血液树突细胞抗原2抗体及其用途
|
|
AU2013361275B2
(en)
|
2012-12-19 |
2016-11-24 |
Amplimmune, Inc. |
Anti-human B7-H4 antibodies and their uses
|
|
MX2015008117A
(es)
|
2012-12-21 |
2016-03-31 |
Amplimmune Inc |
Anticuerpos anti-h7cr.
|
|
US10766960B2
(en)
|
2012-12-27 |
2020-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
DK2956482T3
(en)
|
2013-02-14 |
2017-10-16 |
Innate Pharma |
TREATMENT OF PERFECT T cell lymphoma
|
|
DK2958941T3
(da)
|
2013-02-20 |
2019-06-24 |
Innate Pharma |
Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
JP6676521B2
(ja)
|
2013-03-14 |
2020-04-08 |
マクロジェニクス，インコーポレーテッド |
二重特異性分子、薬学的組成物及びそれらの使用
|
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
HK1219740A1
(zh)
|
2013-03-15 |
2017-04-13 |
Biogen Ma Inc. |
使用抗αVβ5抗体治疗和预防急性肾损伤
|
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
|
BR112015029395A2
(pt)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
Anticorpos anti-b7-h5 e seus usos
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
US9481729B2
(en)
|
2013-09-11 |
2016-11-01 |
The University Of Hong Kong |
Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
WO2015054039A1
(en)
*
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB
|
|
KR20160135190A
(ko)
|
2014-02-14 |
2016-11-25 |
앤드류 에스. 카이 |
혈관형성 암의 치료를 위한 개선된 방법
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
US10280222B2
(en)
|
2014-03-14 |
2019-05-07 |
Innate Pharma |
Humanized antibodies with increased stability
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
CA2947605A1
(en)
|
2014-05-13 |
2015-11-19 |
Bioatla, Llc |
Conditionally active biological proteins
|
|
EP3152235B1
(en)
|
2014-05-29 |
2021-08-25 |
MacroGenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
|
JP6822849B2
(ja)
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的ＮＫｐ４６結合タンパク質
|
|
CA2952532A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
|
WO2016014725A1
(en)
|
2014-07-22 |
2016-01-28 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
|
US10435470B2
(en)
|
2014-08-05 |
2019-10-08 |
Cb Therapeutics, Inc. |
Anti-PD-L1 antibodies
|
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
|
EP3201227A4
(en)
|
2014-09-29 |
2018-04-18 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
|
EP3209687A1
(en)
|
2014-10-23 |
2017-08-30 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
|
BR112017006591A2
(pt)
|
2014-11-06 |
2018-01-16 |
Hoffmann La Roche |
polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
|
|
RS60739B1
(sr)
|
2014-11-17 |
2020-09-30 |
Regeneron Pharma |
Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
|
|
DK3233907T3
(da)
*
|
2014-12-19 |
2021-06-07 |
Genmab As |
Bispecifikke heterodimeriske proteiner hos gnavere
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
CN114773470A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
JP6724023B2
(ja)
*
|
2015-02-09 |
2020-07-15 |
リサーチ ディベロップメント ファウンデーション |
改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
|
|
WO2016149710A2
(en)
|
2015-03-19 |
2016-09-22 |
Duke University |
Hiv-1 neutralizing antibodies and uses thereof
|
|
WO2016149695A1
(en)
|
2015-03-19 |
2016-09-22 |
Duke University |
HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
|
|
AU2016232693B2
(en)
|
2015-03-19 |
2021-08-12 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof
|
|
WO2016149698A2
(en)
|
2015-03-19 |
2016-09-22 |
Duke University |
Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies)
|
|
CA2981312C
(en)
|
2015-03-30 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
WO2016207278A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
|
DK3313876T3
(da)
|
2015-06-23 |
2025-04-22 |
Innate Pharma |
Multispecifikke antigenbindende proteiner
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
LT3353212T
(lt)
|
2015-09-23 |
2021-12-27 |
Regeneron Pharmaceuticals, Inc. |
Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
|
|
CN108136010A
(zh)
|
2015-10-08 |
2018-06-08 |
宏观基因有限公司 |
用于治疗癌症的联合疗法
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
RU2018128215A
(ru)
|
2016-03-15 |
2020-04-15 |
Иннейт Фарма |
Антитела против mica
|
|
TWI781098B
(zh)
|
2016-04-15 |
2022-10-21 |
美商宏觀基因股份有限公司 |
新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
|
|
AU2017257504A1
(en)
|
2016-04-26 |
2018-10-25 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
TWI693940B
(zh)
|
2016-08-05 |
2020-05-21 |
日商中外製藥股份有限公司 |
Ｉｌ-８相關疾病之治療用或預防用組成物
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
AU2017330346C1
(en)
|
2016-09-21 |
2025-03-06 |
Nextcure, Inc. |
Antibodies for Siglec-15 and methods of use thereof
|
|
CN110214147A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
IL15/IL15Rα异源二聚体FC-融合蛋白
|
|
US20190248895A1
(en)
|
2016-10-21 |
2019-08-15 |
Innate Pharma |
Treatment with anti-kir3dl2 agents
|
|
GB201619652D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
KR101872455B1
(ko)
*
|
2016-11-30 |
2018-06-28 |
국민대학교 산학협력단 |
신규한 돌연변이를 포함하는 항체 Ｆｃ 영역
|
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
|
WO2018115262A1
(en)
|
2016-12-23 |
2018-06-28 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
JP7337698B2
(ja)
|
2017-02-28 |
2023-09-04 |
シージェン インコーポレイテッド |
コンジュゲート化のためのシステイン突然変異抗体
|
|
WO2018183520A1
(en)
|
2017-03-28 |
2018-10-04 |
Lyvgen Biopharma Holdings Limited |
Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
|
|
US10767164B2
(en)
|
2017-03-30 |
2020-09-08 |
The Research Foundation For The State University Of New York |
Microenvironments for self-assembly of islet organoids from stem cells differentiation
|
|
EP3615052B1
(en)
|
2017-04-27 |
2023-01-25 |
The University of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
|
TW202515616A
(zh)
|
2017-06-26 |
2025-04-16 |
英屬開曼群島商百濟神州有限公司 |
抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
WO2019011918A1
(en)
|
2017-07-10 |
2019-01-17 |
International - Drug - Development - Biotech |
TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
|
|
CN118909118A
(zh)
|
2017-09-07 |
2024-11-08 |
奥古斯塔大学研究所公司 |
程序性细胞死亡蛋白1抗体
|
|
EP3710589A4
(en)
|
2017-11-14 |
2021-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-C1S ANTIBODIES AND METHOD OF USING
|
|
AU2018371114A1
(en)
|
2017-11-21 |
2020-05-07 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
CN111655729B
(zh)
|
2017-12-19 |
2023-10-20 |
瑟罗泽恩奥普瑞汀公司 |
抗卷曲蛋白抗体和使用方法
|
|
CN111699003B
(zh)
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
EP3732201A4
(en)
|
2017-12-19 |
2022-04-20 |
Surrozen Operating, Inc. |
WNT SURROGATES AND THEIR USES
|
|
US11078283B2
(en)
|
2018-01-17 |
2021-08-03 |
Apexigen, Inc. |
Anti-PD-L1 antibodies and methods of use
|
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
|
PE20210665A1
(es)
|
2018-03-23 |
2021-03-31 |
Bristol Myers Squibb Co |
Anticuerpos contra mica y/o micb y sus usos
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
KR20210003813A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
|
|
CA3104526A1
(en)
|
2018-07-05 |
2020-01-09 |
Surrozen, Inc. |
Multi-specific wnt surrogate molecules and uses thereof
|
|
EP3835321A4
(en)
|
2018-08-10 |
2022-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
|
|
RS66543B1
(sr)
|
2018-08-31 |
2025-03-31 |
Regeneron Pharma |
Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
AU2019359475A1
(en)
|
2018-10-12 |
2021-05-20 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
|
|
EP3873519A1
(en)
|
2018-10-29 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Antibody formulation
|
|
WO2020118293A2
(en)
|
2018-12-07 |
2020-06-11 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
CA3125945A1
(en)
|
2019-01-22 |
2020-07-30 |
Innate Pharma |
Treatment of t cell lymphoma
|
|
CN113874392B
(zh)
|
2019-03-28 |
2025-10-21 |
丹尼斯科美国公司 |
工程化抗体
|
|
MX2021013441A
(es)
|
2019-05-15 |
2021-12-10 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigenos, composicion farmaceutica y metodo.
|
|
CN118806923A
(zh)
|
2019-08-07 |
2024-10-22 |
乐天医药生技股份有限公司 |
西妥昔单抗-ir700偶联物组合物
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
CN115427447B
(zh)
|
2020-01-17 |
2025-02-18 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
|
TW202233656A
(zh)
|
2020-11-16 |
2022-09-01 |
美商蘇羅森營運公司 |
肝特異性wnt訊號增強分子及其用途
|
|
JP2024500920A
(ja)
|
2020-12-23 |
2024-01-10 |
カンタージア アクチエボラーグ |
抗ｉｌ１ｒａｐ抗体
|
|
MX2023011310A
(es)
|
2021-03-26 |
2023-10-05 |
Innate Pharma |
Anclajes de citocina para proteinas de celulas nk de union a nkp46.
|
|
US12565529B2
(en)
|
2021-05-24 |
2026-03-03 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
US20250002601A1
(en)
|
2021-06-09 |
2025-01-02 |
Innate Pharma |
Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
BR112023025331A2
(pt)
|
2021-06-09 |
2024-02-27 |
Innate Pharma |
Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
|
US12467921B2
(en)
|
2021-08-31 |
2025-11-11 |
Versitech Limited |
Antibodies and assays for detection of Burkholderia mallei
|
|
KR102939464B1
(ko)
*
|
2021-09-17 |
2026-03-13 |
고려대학교 산학협력단 |
FcγRⅢa 결합력이 향상된 당화 Fc 변이체들
|
|
KR102828032B1
(ko)
*
|
2021-09-17 |
2025-07-01 |
고려대학교 산학협력단 |
Fc 감마 수용체와의 결합력이 증대된 Fc 변이체
|
|
KR102939471B1
(ko)
*
|
2021-09-17 |
2026-03-13 |
고려대학교 산학협력단 |
선택적 FcγRⅢa 결합력이 증가된 당화 Fc 변이체들
|
|
CN118284627A
(zh)
*
|
2021-11-08 |
2024-07-02 |
广州昂科免疫生物技术有限公司 |
包含072核心肽的融合蛋白及其用途
|
|
JP2025504020A
(ja)
|
2022-01-28 |
2025-02-06 |
ジョージアミューン・インコーポレイテッド |
Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
|
|
KR20250035053A
(ko)
|
2022-06-07 |
2025-03-11 |
리제너론 파아마슈티컬스, 인크. |
T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
|
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
|
CN119301155A
(zh)
|
2022-07-19 |
2025-01-10 |
百进生物科技公司 |
抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法
|
|
CN119968395A
(zh)
|
2022-08-18 |
2025-05-09 |
百进生物科技公司 |
抗axl抗体、其抗原结合片段及其制备和使用方法
|
|
US20260071003A1
(en)
|
2022-09-01 |
2026-03-12 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
|
WO2024092031A1
(en)
|
2022-10-25 |
2024-05-02 |
Seismic Therapeutic, Inc. |
VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
|
|
CN121219315A
(zh)
|
2023-03-03 |
2025-12-26 |
塞德斯医疗公司 |
抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
|
|
WO2024231251A1
(en)
|
2023-05-05 |
2024-11-14 |
Cantargia Ab |
Anti-il1rap antibodies
|
|
WO2024243217A1
(en)
|
2023-05-25 |
2024-11-28 |
BioLegend, Inc. |
Ceacam6 binding antibodies and antigen-binding fragments thereof
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|